Apellis Pharmaceuticals, Inc. Material Event - What Happened

This report explains the latest news from Apellis Pharmaceuticals in plain English. If you follow the company, here is what you need to know.

1. What happened?

Biogen has acquired Apellis Pharmaceuticals in a deal worth about $5.3 billion. After a successful buyout offer, the two companies merged. As of May 14, 2026, Apellis is now a wholly owned subsidiary of Biogen.

2. Why did it happen?

Apellis creates treatments for rare diseases and serious eye conditions. Its flagship drug, SYFOVRE®, treats geographic atrophy caused by age-related macular degeneration. Biogen wanted to add these specialized medicines to its own collection. On April 15, 2026, Biogen offered to buy all outstanding Apellis shares. The deal closed after 82.4% of shareholders agreed to sell, allowing the merger to proceed without a formal vote.

3. What does this mean for the company?

The transition is complete. The entire Apellis Board of Directors resigned, and the company’s internal rules now match Biogen’s corporate structure. Apellis has also delisted its stock from the Nasdaq. You can no longer trade these shares on the public market.

4. Why does this matter?

• For Stockholders: Your shares were converted into the right to receive $41.00 in cash per share, minus any taxes. You also received one "Contingent Value Right" (CVR) per share. Think of this as a performance bonus. If SYFOVRE® hits specific sales goals between 2027 and 2031, you could receive up to $4.00 more per share.
• For Note Holders: If you held Apellis’s 3.500% Convertible Senior Notes, your rights have changed. These notes now convert into a mix of cash and CVRs. For every $1,000 of notes, you are entitled to roughly $1,039 to $1,080 in cash, plus a set number of CVRs.
• For the Business: Apellis is no longer a public company. It has ended its stock incentive plans and settled its debts. It now operates as a private entity under Biogen’s oversight.

5. Who is affected?

• Investors: The stock is no longer tradeable. Check your brokerage statements to ensure you received your cash and CVRs.
• Patients: Operations should continue under Biogen. Biogen will use its global reach to help distribute Apellis’s existing treatments.
• Employees: The leadership change is finished. A Biogen-appointed director, Michael Dambach, now oversees the subsidiary.

6. What happens next?

Success now depends on how well SYFOVRE® sells. The CVR payout depends on the drug reaching annual sales between $1.5 billion and $2 billion during the target period.

7. What should you know?

• The "Bonus" isn't guaranteed: The CVRs carry risk. The extra $4.00 per share depends entirely on the drug’s future sales. There is no guarantee these targets will be met.
• Check your statements: Contact your broker to confirm your account shows the correct cash payout and CVRs. These are non-transferable and may not look like standard stocks in your account.

Disclaimer: I am an AI, not a financial advisor. This summary is for informational purposes only and does not constitute financial advice. Always do your own research before making investment decisions.